Elizabeth A.G. Cisar, PhD

Elizabeth A.G. Cisar, PhD
Patent Agent
McNeill Baur PLLC
Two Bala Plaza, Suite 300 #507
Bala Cynwyd, PA 19004

Fusing broad technical expertise and IP experience to protect your cutting edge inventions 

Elizabeth Cisar, PhD, focuses her practice on patent drafting and US and foreign patent prosecution. She also provides patent portfolio strategy and assists with due diligence investigations, as well as patentability, validity, and infringement analyses. Elizabeth evaluates clients’ business priorities and the competitive landscape when  optimizing intellectual property protection.

Elizabeth’s scientific background includes synthetic chemistry, molecular biology, proteomics, and assay development. Her broad technical background facilitates deep understanding of life science technologies, and her intellectual property experience spans pharmaceutical drug candidates and methods of treatment across a variety of therapeutic areas.

Prior to joining McNeill Baur PLLC, Elizabeth was a patent agent at Ionis Pharmaceuticals, Inc., a publicly traded biotechnology company, where she worked with the scientific and legal teams to strategically protect key platform technologies and drug candidates.

Elizabeth performed her postdoctoral work at The Scripps Research Institute where she developed a nucleotide probe for use in proteomics and molecular biologic studies of GTPases. In her doctoral work at The Rockefeller University, she studied mechanisms of receptor mediated microbial signaling using molecular biology techniques in combination with synthesis of modified peptides.

Select Publications

A GTP Affinity Probe Highlights Flexibility in Purine Nucleotide Selectivity,” J. Am. Chem. Soc. 135(12): 4676-9 (2013) (coauthor).

 “Sphingosine 1-Phosphate Receptor 1 (S1P1) Upregulation and Amelioration of Experimental Autoimmune Encephalomyelitis by an S1P1 Antagonist,”Mol. Pharmacol. 83(2): 316-21 (2013) (coauthor).

 “Symmetric Signalling within Asymmetric Dimers of the Staphylococcus aureus Receptor Histidine Kinase AgrC,” Mol. Microbiol. 74(1): 44-57 (2009) (coauthor).

 “Cyclic Peptide Inhibitors of Staphylococcal Virulence Prepared by Fmoc-based Thiolactone Peptide Synthesis,” J. Am. Chem. Soc. 130(14): 4914-24 (2008) (coauthor).

 “Molecular Mechanisms of agr Quorum Sensing in Virulent Staphylococci,” Chembiochem 8(8): 847-55 (2007) (coauthor).


US Patent and Trademark Office



The Rockefeller University

PhD, Chemical Biology, 2009


University of North Carolina

BS, Biology, 2001